lball
Client
Joined March 2021
ContestContests
Logos
Status
Prize *
Fortify
PsiOxus aims to be the world’s leading company in tumour re-engineering, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage company pioneering systemic oncology products that drive reprogramming of the tumour microenvironment to overcome the central challenge of resistance to therapy. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Target audience: Medical professionals and patients
325
Logos
Complete
Status
$475
Prize
Fortify
PsiOxus aims to be the world’s leading company in tumour re-engineering, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage company pioneering systemic oncology products that drive reprogramming of the tumour microenvironment to overcome the central challenge of resistance to therapy. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Target audience: Medical professionals and patients
325
Complete
$475
NEBULA (clinical trial - PsiOxus Therapeutics Ltd)
PsiOxus aims to be the world’s leading company in tumour re-engineering, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage company pioneering systemic oncology products that drive reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Target audience: Medical professionals and patients
161
Logos
Complete
Status
$475
Prize
NEBULA (clinical trial - PsiOxus Therapeutics Ltd)
PsiOxus aims to be the world’s leading company in tumour re-engineering, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage company pioneering systemic oncology products that drive reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Target audience: Medical professionals and patients
161
Complete
$475
MOAT
PsiOxus aims to be the world’s leading company in tumour re-engineering, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage company pioneering systemic oncology products that drive reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Target audience: Medical professionals and patients
217
Logos
Complete
Status
$475
Prize
MOAT
PsiOxus aims to be the world’s leading company in tumour re-engineering, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage company pioneering systemic oncology products that drive reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Target audience: Medical professionals and patients
217
Complete
$475
* The Prize Package includes the Designer prize and all LogoTournament fees.